ArticleProceedings of the National Academy of Sciences of the United States of America2025
Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Structural evolution of ionizable lipids for nucleic acid delivery.Nature reviews. Chemistry · 2026Review
- Overcoming hepatic tropism: Precision engineering of lipid nanoparticles for extrahepatic RNA delivery.Materials today. Bio · 2026Review
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- A Cascaded DNA Nanocircuit for Multi-Signal-Responsive Precision siRNA Delivery in Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Spatio-temporal targeting of cardiac cells with lipid nanoparticles after myocardial infarction.Journal of molecular and cellular cardiology plus · 2026Article
- RNA-Based Therapies for Treating Monogenic Cardiomyopathies.The Canadian journal of cardiology · 2026Review
- Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Mechanisms and Therapeutic Potential of Human Cardiomyocyte Proliferation.Journal of cardiovascular development and disease · 2026Review
- Small Interfering RNA (siRNA) as a Targeted Therapy for Acute Respiratory Distress Syndrome: Evidence from Experimental Models.International journal of molecular sciences · 2026Review
- Role of Homeobox (HOX) Genes in Adult Cardiovascular Disease: From Developmental Regulators to Therapeutic Targets.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Vladimir V ShuvaevDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-2449-460X
Ying K TamAcuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.
Benjamin W LeeCardiovascular Institute, Perelman School of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA 19104.
Jacob W MyersonDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Alan HerbstDivision of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-1301-7851
Raisa Yu KiselevaDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Patrick M GlassmanDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-3786-0437
Hamideh ParhizDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Mohamad-Gabriel AlamehDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Norbert PardiDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-1008-6242
Hiromi MuramatsuDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-1544-1493
Tea I ShuvaevaDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-5156-6088
Evguenia ArguiriDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Oscar A Marcos-ContrerasDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-1247-4882
Elizabeth D HoodDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-6829-8339
Taylor V BrysgelDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-4791-6492
Jia NongDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-9210-7707
Tyler E PappDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Deborah M EatonCardiovascular Institute, Perelman School of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA 19104.
Rachel RileyDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104.
Rohan PalankiDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-5168-5634
Kiran MusunuruCardiovascular Institute, Perelman School of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA 19104.
Jacob S BrennerDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Michael J MitchellDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-3628-2244
Victor A FerrariCardiovascular Institute, Perelman School of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA 19104.
Barbara L MuiAcuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.
Sean C SempleAcuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.
Sherry A WepplerAcuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.ORCID 0009-0009-9335-3174
Pavan AtluriDivision of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-0229-085X
Kenneth B MarguliesCardiovascular Institute, Perelman School of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-8093-4465
Drew WeissmanDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-1501-6510
Vladimir R MuzykantovDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-6648-1204
Funding
Training Program in Cardiovascular Biology and MedicineT32HL007843 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Sharlene M Day · 1996 to 2026
$11.0MVascular Targeting of Nanocarriers for RNAR01HL155106 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R, WEISSMAN, DREW · 2021 to 2024
$3.1MCardiac delivery of RNA to treat contractile disorderR01HL169448 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Kenneth Ber Margulies, Vladimir R Muzykantov · 2024 to 2026
$2.4MNHLBI NIH HHS R01 HL155106NHLBI NIH HHS R01 HL169448NHLBI NIH HHS T32 HL007843NIH HHS RO1 HL155106
Abstract
Lipid nanoparticles (LNP) represent a versatile platform for improving delivery of therapeutic nucleic acids. Yet, delivery to the myocardium remains a formidable challenge due to local barriers in the heart and systemic hindrances. In particular, plasma apolipoprotein E (apoE) directs LNP to the liver, limiting potential extrahepatic delivery. Here, we report a cardiotropic LNP (cLNP), which within 30 min post-intravenous injection accumulates in the heart of ApoE knockout (
Indexed as
Myocardial ContractionMyocardiumRNA, Small InterferingAnimalsApolipoproteins ELipidsMaleMiceMice, KnockoutMyocytes, CardiacNanoparticlesRatsSarcoplasmic Reticulum Calcium-Transporting ATPasesApolipoproteins EAtp2a2 protein, mouseLipidsRNA, Small InterferingSarcoplasmic Reticulum Calcium-Transporting ATPasescardiac drug deliverylipid nanoparticlesmRNASERCA2siRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.